72% of BROVANA® (arformoterol tartrate) Inhalation Solution patients reported improvement in overall COPD symptoms1
From pooled analysis of two identical 12-week trials assessing BROVANA 15 mcg twice daily vs placebo.
Data from 2 identical 12-week, double-blind, placebo-controlled, randomized, multicenter trials (trials A & B) assessing the efficacy and tolerability of nebulized BROVANA® (arformoterol tartrate) Inhalation Solution 15 mcg twice daily (n=288) vs placebo (n=293) in patients with COPD.
* Patients rated overall COPD symptoms compared with before BROVANA study enrollment using the following scale: much better, moderately better, slightly better, the same, slightly worse, moderately worse, much worse.
- All COPD patients (including those in placebo group) received rescue albuterol and supplemental ipratropium for use as needed throughout trial, except within 6 hours of PFT visit
- Patients who reported their overall COPD symptoms as slightly, moderately, or much better were considered to have improvement vs baseline
The five most common adverse events reported in COPD patients taking BROVANA® (arformoterol tartrate) Inhalation Solution 15 mcg bid and occurring more frequently than in COPD patients taking placebo were: pain (8% vs 5% for placebo), chest pain (7% vs 6% for placebo), back pain (6% vs 2% for placebo), diarrhea (6% vs 4% for placebo), and sinusitis (5% vs 4% for placebo).